Biogen in new multiple sclerosis study

Biogen Idec Inc. of Cambridge said today it is participating in a new study of a potential treatment for a form of multiple sclerosis, a disease of the central nervous systems.

Biogen Idec is conducting the Phase 2 study with UCB of Belgium; last October, the companies entered an agreement to co-develop and co-commercialize CDP323, a small molecule compound under development for relapsing-remitting multiple sclerosis.

The study is designed to enroll more than 200 patients with relapsing-remitting MS who have failed earlier treatment with a beta-interferon, the companies said.
(By Chris Reidy, Globe staff)